Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522
Recruiting
The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/20/2025
Locations: Texas Oncology Central/South Texas, Austin, Texas
Conditions: MTAP-deleted NSCLC
Register for Updates
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT06581328
Recruiting
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), partici... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/20/2025
Locations: Amel Med LLC, Georgetown, Texas
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
NCT06566742
Recruiting
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
Register for Updates
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
NCT06478212
Recruiting
The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. The study will begin as a Phase Ib study to determine the RCD and then will transition to a Phase II study to assess the clinical efficacy of vorasidenib at the RCD in combination with TMZ. During the treatment period participants will have study visits on day 1 and 22 of each cycle, with additional v... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/20/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: IDH1-mutant Glioma, IDH2-mutant Glioma
Register for Updates
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045
Recruiting
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: Amarillo Medical Specialists, Amarillo, Texas
Conditions: Asthma
Register for Updates
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/20/2025
Locations: Site 110, Dallas, Texas
Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Register for Updates
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
NCT06364215
Recruiting
The purpose of this study is to compare the efficacy and safety between pulmonary vein isolation (PVI) alone versus PVI with left atrial (LA) posterior wall isolation (PWI) using pulsed-field ablation (PFA) in the treatment of patients with paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
08/20/2025
Locations: Orion Medical, Houston, Texas
Conditions: Atrial Fibrillation Paroxysmal
Register for Updates
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951
Recruiting
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/20/2025
Locations: Texas Oncology - Dallas Fort Worth, Dallas, Texas
Conditions: Thoracic Tumors, Non-small Cell Lung Cancer
Register for Updates
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
NCT06312020
Recruiting
The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: Tekton Research, LLC - W Gate Blvd - Austin - PPDS, Austin, Texas
Conditions: Sjogren's Syndrome
Register for Updates
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: ANESC Research, El Paso, Texas
Conditions: Focal Epilepsy
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/20/2025
Locations: Research Site, Abilene, Texas
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408
Recruiting
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS. 2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS 3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Amarillo Center For Clinical Research, Amarillo, Texas
Conditions: Sjögren's Syndrome (SS)
Register for Updates